Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.41 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3654478 | 0.83 | ADORA2A (0.40) | ADORA2AADORA2BADORA1KDM4EALDH1A1 | |
| SCHEMBL163775 | 0.79 | KMT2A (0.42) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL5113117 | 0.78 | FEN1 (0.41) | TARBP2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL20771829 | 0.78 | GLP1R (0.44) | GLP1RTARBP2KDM4EALDH1A1GAA | |
| SCHEMBL28900166 | 0.78 | ADORA2A (0.57) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20785461 | 0.78 | GLP1R (0.44) | GLP1RTARBP2KDM4EALDH1A1GAA | |
| SCHEMBL16505979 | 0.77 | CDK9 (0.48) | ADORA2AADORA2BADORA1NPC1RAB9A | |
| SCHEMBL6289467 | 0.77 | LMNA (0.45) | ADORA2AADORA2BKDM4EALDH1A1GAA | |
| SCHEMBL29495184 | 0.76 | CD38 (0.56) | ADORA2AADORA2BADORA1KDM4EALDH1A1 | |
| SCHEMBL24261170 | 0.75 | ADORA2A (0.68) | ADORA2AADORA2BADORA1RAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-26 | — | — | US | disclosed |
| CN-119431323-A | Heterobicyclic amides as CD38 inhibitors | 贝林格尔·英格海姆国际有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240368167-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-11-07 | — | — | US | disclosed |
| CN-114423753-B | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2024-09-17 | — | — | CN | disclosed |
| US-11987584-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-21 | — | — | US | disclosed |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | RIBON THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| EP-4003980-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | Ribon Therapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114423753-A | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-2207780-B1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | VERNALIS R&D LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-8354415-B2 | Thienopyrimidine compounds and compositions | VERNALIS (R&D) LTD. (GB) | 2013-01-15 | — | — | US | disclosed |
| US-8354415-B2 | Thienopyrimidine compounds and compositions | VERNALIS (R&D) LTD. (GB) | 2013-01-15 | — | — | US | disclosed |
| US-8354415-B2 | Thienopyrimidine compounds and compositions | VERNALIS (R&D) LTD. (GB) | 2013-01-15 | — | — | US | disclosed |
| US-20100298349-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | VERNALIS (R&D) LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298349-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | VERNALIS (R&D) LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298349-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | VERNALIS (R&D) LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2207780-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | Vernalis (R&D) Ltd. (GB) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009037468-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | VERNALIS (R & D) LTD. (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037468-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | VERNALIS (R & D) LTD. (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368167-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | ADORA2A 671/4885ADORA2B 972/4885ADORA1 2022/4885 |
| US-20100298349-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | ADORA2B, CYP2B6, RRM2B | ADORA2A 51/4885ADORA2B 1/4885ADORA1 79/4885 |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | ADORA2A 671/4885ADORA2B 972/4885ADORA1 2022/4885 |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | ADORA2A 671/4885ADORA2B 972/4885ADORA1 2022/4885 |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, CD22, CD79B | ADORA2A 847/4885ADORA2B 754/4885ADORA1 919/4885 |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | ADORA2A 671/4885ADORA2B 972/4885ADORA1 2022/4885 |
| US-11987584-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | ADORA2A 671/4885ADORA2B 972/4885ADORA1 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.